As the equity markets continue their downward trajectory, the Indian companies’ foreign promoters are anxious to exit. The pharmaceutical MNC - Fresenius Kabi Oncology, is the first prey to this mayhem as its promoters, in a letter to the company dated May 30, 2012, have proposed to delists it from the stock exchanges. This news has crashed the stock by nearly 30%.
Fresenius Kabi Oncology is currently trading at Rs. 96.50, down by 11.60 points or 10.73% from its previous closing of Rs. 108.10 on the BSE.
The scrip opened at Rs. 91.55 and has touched a high and low of Rs. 98.90 and Rs. 87.15 respectively. So far 838244 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 176.00 on 17-Apr-2012 and a 52 week low of Rs. 81.65 on 20-Dec-2011.
Last one week high and low of the scrip stood at Rs. 145.40 and Rs. 108.10 respectively. The current market cap of the company is Rs. 1473.89 crore.
The promoters holding in the company stood at 90.00% while Institutions and Non-Institutions held 2.45% and 7.55% respectively.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1659.55 |
| Dr. Reddys Lab | 1218.20 |
| Cipla | 1229.75 |
| Zydus Lifesciences | 930.05 |
| Lupin | 2313.45 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: